AEM-28
ApoE/ApoA-I chimeric peptide AEM-28
28 Amino Acids · MW: ~3200 Da
Amino Acids
28
Molecular Weight
~3200 Da
Half-life
Short; formulation-dependent
Research Score
4.3
Studies
29
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is AEM-28?
AEM-28 is a synthetic apolipoprotein E/apolipoprotein A-I chimeric peptide studied for lipid lowering and atheroprotection. It is a real research peptide with literature support for improving cholesterol transport and reducing atherosclerotic risk markers.
Key Benefits & Mechanisms
lowers atherogenic lipids
improves lipoprotein clearance
supports HDL remodeling
may reduce plaque burden
Research Summary
AEM-28 has been explored as a dual-function lipid peptide with apoE-like and apoA-I-like properties. Preclinical work suggests benefits on serum lipids, cholesterol transport, and atherosclerosis-related endpoints.
Related Peptides
Carperitide
Recombinant human atrial natriuretic peptide (α-hANP)
Recombinant human atrial natriuretic peptide used mainly in acute heart failure and perioperative volume overload. It promotes natriuresis, vasodilation, and suppression of RAAS signaling to lower preload and afterload.
CardiovascularNesiritide
Recombinant human B-type natriuretic peptide (BNP-32)
Synthetic BNP used to counteract fluid overload and elevated cardiac filling pressures. It increases cyclic GMP, causing venous and arterial vasodilation plus natriuresis.
CardiovascularUlaritide
Synthetic human urodilatin
Urodilatin is a renal natriuretic peptide derived from the proANP precursor and studied as an IV heart-failure therapy. It produces strong natriuresis and vasodilation with a relatively rapid onset.
CardiovascularCenderitide
CD-NP chimeric natriuretic peptide
Cenderitide is a designer natriuretic peptide combining features of CNP and dendroaspis natriuretic peptide. It was engineered to provide balanced natriuretic and vasodilatory activity with potential renal-sparing effects.
Cardiovascular